| Literature DB >> 34255114 |
Johannes Baur1, Michaela Ramser1, Nicola Keller2, Filip Muysoms3, Jörg Dörfer4, Armin Wiegering5, Lukas Eisner1, Ulrich A Dietz6.
Abstract
Endoscopic management of umbilical and incisional hernias has adapted to the limitations of conventional laparoscopic instruments over the past 30 years. This includes the development of meshes for intraperitoneal placement (intraperitoneal onlay mesh, IPOM), with antiadhesive coatings; however, adhesions do occur in a significant proportion of these patients. Minimally invasive procedures result in fewer perioperative complications, but with a slightly higher recurrence rate. With the ergonomic resources of robotics, which offers angled instruments, it is now possible to implant meshes in a minimally invasively manner in different abdominal wall layers while achieving morphologic and functional reconstruction of the abdominal wall. This video article presents the treatment of ventral and incisional hernias with mesh implantation into the preperitoneal space (robot-assisted transabdominal preperitoneal ventral hernia repair, r‑ventral TAPP) as well as into the retrorectus space (r-Rives and robotic transabdominal retromuscular umbilical prosthetic repair, r‑TARUP, respectively). The results of a cohort study of 118 consecutive patients are presented and discussed with regard to the added value of the robotic technique in extraperitoneal mesh implantation and in the training of residents.Entities:
Keywords: Incisional hernia; Linea alba; Minimally invasive; Primary ventral hernia; Retrorectus mesh; Umbilical hernia
Mesh:
Substances:
Year: 2021 PMID: 34255114 PMCID: PMC8384833 DOI: 10.1007/s00104-021-01450-5
Source DB: PubMed Journal: Chirurg ISSN: 0009-4722 Impact factor: 0.955




| rv-TAPP ( | r‑Rives ( | ||||
|---|---|---|---|---|---|
| 52,3 | (±13,7) | 62,1 | (±13,3) | ||
| 25 | (28,4) | 15 | (50,0) | ||
| 30,7 | (±6,4) | 29,2 | (±5,4) | 0,250 | |
| 37 | (42,0) | 14 | (46,7) | 0,659 | |
| 70 | (79,5) | 24 | (80,0) | 0,957 | |
| 18 | (20,5) | 6 | (20,0) | ||
| 20 | (22,7) | 3 | (10,0) | 0,062 | |
| 20 | (22,7) | 4 | (13,3) | ||
| 16 | (18,2) | 12 | (40,0) | ||
| 32 | (36,4) | 11 | (36,7) | ||
| 43 | (48,9) | 12 | (40,0) | 0,400 | |
| 10 | (11,4) | 3 | (10,0) | 0,836 | |
| 13 | (14,8) | 7 | (23,3) | 0,280 | |
| 8 | (9,1) | 5 | (16,7) | 0,252 | |
| 3 | (3,4) | 0 | (0,0) | 0,591 | |
| Tiefe Venenthrombose | 3 | (3,4) | 0 | (0,0) | 0,305 |
| Lungenembolie | 1 | (1,1) | 0 | (0,0) | 0,557 |
| 2 | (2,3) | 0 | (0,0) | 0,405 | |
| 16 | (18,2) | 6 | (20,0) | 0,825 | |
| DOAC | 5 | (5,7) | 1 | (3,3) | 0,805 |
| Marcumar | 1 | (1,1) | 0 | (0,0) | 0,557 |
| Plättchenaggregationshemmer | 11 | (12,5) | 5 | (16,7) | 0,643 |
| 8 | (9,1) | 4 | (13,3) | 0,425 | |
| 64 | (72,7) | 18 | (60,0) | ||
| 16 | (18,2) | 8 | (26,7) | ||
ASA American Society of Anesthesiology Score, BMI Body-Mass-Index, COPD „chronic obstructive pulmonary disease“, DOAC „duale orale Antikoagulation“MW Mittelwert, r‑Rives robotische transabdominelle retromuskuläre umbilikale Patchplastik [r-TARUP], rv-TAPP robotische ventrale transabdominelle präperitoneale Patchplastik, SA Standardabweichung
| rv-TAPP ( | r‑Rives ( | ||||
|---|---|---|---|---|---|
| 53 | (60,2) | 10 | (33,3) | ||
| 22 | (25,0) | 1 | (3,3) | ||
| 3 | (3,4) | 0 | (0,0) | ||
| 4 | (4,5) | 2 | (6,7) | ||
| 6 | (6,8) | 17 | (56,7) | ||
| 38 | (43,2) | 10 | (33,3) | 0,797 | |
| 2,3 | (±1,1) | 4,9 | (±1,1) | ||
| 2,2 | (±1,0) | 4,2 | (±1,0) | ||
| 8,8 | (±9,4) | 20,1 | (±17,7) | ||
| 13 | (14,8) | 3 | (10,0) | ||
| 1 | (1,1) | 8 | (26,7) | ||
| 74 | (84,1) | 19 | (63,3) | ||
| 11,6 | (±3,5) | 16,1 | (±4,0) | ||
| 9,0 | (±2,1) | 12,7 | (±2,9) | ||
| 107,8 | (±56,0) | 205,5 | (±77,6) | ||
| 30,1 | (±50,1) | 16,5 | (±12,8) | 0,142 | |
| 73 | (83,0) | 2 | (6,7) | ||
| 15 | (17,0) | 27 | (90,0) | ||
| 0 | (0,0) | 1 | (3,3) | ||
| 1 | (1,1) | 0 | (0,0) | 0,828 | |
| 82 | (93,2) | 28 | (93,3) | ||
| 5 | (5,7) | 2 | (6,7) | ||
| 2 | (2,3) | 0 | (0,0) | 0,405 | |
| 82,9 | (±21,0) | 109,1 | (±32,4) | ||
EHS Klassifikation der Europäischen Herniengesellschaft [24], MW Mittelwert, r‑Rives robotische transabdominelle retromuskuläre umbilikale Patchplastik [r-TARUP], rv-TAPP robotische ventrale transabdominelle präperitoneale Patchplastik, SA Standardabweichung
| rv-TAPP ( | r‑Rives ( | ||||
|---|---|---|---|---|---|
| 15 | (17,0) | 3 | (10,0) | 0,354 | |
| 1,5 | (±0,6) | 2,7 | (±1,7) | ||
| 2,3 | (±2,0) | 2,6 | (±1,5) | 0,529 | |
| 16 | (18,2) | 9 | (30,0) | 0,171 | |
| Serom (nach Morales-Conde) | 14 | (15,9) | 7 | (23,3) | 0,358 |
| – Grad I | 1 | (1,1) | – | – | |
| – Grad II | 11 | (12,5) | 5 | (16,7) | |
| – Grad III | 2 | (2,3) | 0 | (0,0) | |
| – Grad IV | – | – | 2 | (6,7) | |
| Hämatom | 3 | (3,4) | 3 | (10,0) | 0,155 |
| Hautnekrose | – | – | 1 | (3,3) | 0,085 |
| 5 | (5,7) | 1 | (3,3) | 0,613 | |
| 1 | (1,1) | 1 | (3,3) | 0,557 | |
| 2 | (2,3) | – | – | 0,405 | |
| Grad I | 23 | (20) | 9 | (8) | 0,661 |
| Grad II | 2 | (2) | – | – | 0,405 |
| Grad III | – | – | 1 | (1) | 0,085 |
| Grad IV | – | – | 1 | (1) | 0,085 |
| 2,7 | (±5,6) | 4,4 | (±8,1) | 0,191 | |
| 74 | (84,1) | 28 | (93,3) | 0,201 | |
| – | – | – | – | 1,000 | |
| 5 | (6,7) | – | – | 0,161 | |
| 10 | (13,3) | 7 | (25,0) | 0,155 | |
| 1 | (1,3) | 1 | (3,7) | 0,446 | |
CCI Charlson Comorbidity Score, r‑Rives robotische transabdominelle retromuskuläre umbilikale Patchplastik [r-TARUP], rv-TAPP robotische ventrale transabdominelle präperitoneale Patchplastik, SSO „surgical site occurrence“, VAS visuelle Analogskala
aBei Patienten mit stationärem Aufenthalt
| SSO− | SSO+ | ||||
|---|---|---|---|---|---|
| ( | ( | ||||
| 54,1 | (±14,2) | 57,6 | (±14,1) | 0,265 | |
| 29 | (31,2) | 11 | (44,0) | 0,229 | |
| 29,9 | (±6,2) | 31,8 | (±5,8) | 0,179 | |
| 38 | (40,9) | 13 | (52,0) | 0,318 | |
| 42 | (45,2) | 13 | (52,0) | 0,542 | |
| 8 | (8,6) | 5 | (20,0) | 0,106 | |
| 14 | (15,1) | 6 | (24,0) | 0,289 | |
| 11 | (11,8) | 2 | (8,0) | 0,587 | |
| 18 | (19,4) | 4 | (16,0) | 0,702 | |
| ASA I | 11 | (11,8) | 1 | (4,0) | 0,347 |
| ASA II | 65 | (69,9) | 17 | (68,0) | |
| ASA III | 17 | (18,3) | 7 | (28,0) | |
| 50 | (53,8) | 13 | (52,0) | 0,764 | |
| 17 | (18,3) | 6 | (24,0) | ||
| 23 | (24,7) | 6 | (24,0) | ||
| 3 | (3,2) | – | – | ||
| 34 | (36,6) | 13 | (52,0) | 0,567 | |
| 10,6 | (±11,5) | 15,7 | (±17,2) | 0,085 | |
| 72 | (77,4) | 16 | (64,0) | 0,171 | |
| 21 | (22,6) | 9 | (36,0) | ||
| 19 | (20,4) | 8 | (32,0) | 0,221 | |
| 132,9 | (±77,8) | 131,9 | (±65,8) | 0,953 | |
| 29,7 | (±48,7) | 14,9 | (±10,3) | 0,143 | |
| 61 | (65,6) | 14 | (56,0) | 0,553 | |
| 31 | (33,3) | 11 | (44,0) | ||
| 1 | (1,1) | – | – | ||
| 88,9 | (±26,8) | 91,9 | (±27,3) | 0,625 | |
ASA American Society of Anesthesiology Score, COPD „chronic obstructive pulmonary disease“,r‑Rives robotische transabdominelle retromuskuläre umbilikale Patchplastik [r-TARUP], rv-TAPP robotische ventrale transabdominelle präperitoneale Patchplastik, SSE „surgical site event“ (Wundkomplikation), SSO „surgical site occurrence“
aSchnitt-Naht-Zeit beinhaltet die gesamte Operationszeit, inklusive des An- und Andockens